Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti–CTLA-4 treatment prolongs overall survival in patients with melanom...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:N Engl J Med
Huvudupphovsmän: Snyder, Alexandra, Makarov, Vladimir, Merghoub, Taha, Yuan, Jianda, Zaretsky, Jesse M., Desrichard, Alexis, Walsh, Logan A., Postow, Michael A., Wong, Phillip, Ho, Teresa S., Hollmann, Travis J., Bruggeman, Cameron, Kannan, Kasthuri, Li, Yanyun, Elipenahli, Ceyhan, Liu, Cailian, Harbison, Christopher T., Wang, Lisu, Ribas, Antoni, Wolchok, Jedd D., Chan, Timothy A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2014
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4315319/
https://ncbi.nlm.nih.gov/pubmed/25409260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1406498
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk